Global Life Sciences Practice Receives The Deal’s “Dealmaker of the Year” and “Deal of the Year” Honors

Practices: Life Sciences, Mergers & Acquisitions, Life Sciences Licensing, Collaborations & Joint Ventures, Life Sciences Mergers & Acquisitions, Capital Markets

On March 26, The Deal Middle Market Awards honored Ropes & Gray’s global life sciences practice with two important industry accolades–“Healthcare & Pharma Deal of the Year” and also “Healthcare & Pharma Dealmaker of the Year.”

The firm garnered The Deal’s “Healthcare & Pharma Deal of the Year” for its work advising Bain Capital on the creation of Cerevel Therapeutics. Cerevel, created in 2018 in partnership with Pfizer, is a biopharmaceutical company focused on developing drugs to treat disorders that affect the function of the central nervous system including Parkinson’s, Alzheimer’s, epilepsy, and schizophrenia. Funds advised by Bain committed $350 million with the ability to provide additional capital; Pfizer contributed a portfolio of pre-commercial neuroscience assets and retained a 25 percent equity position.

The Deal also named life sciences partner Marc Rubenstein “Healthcare & Pharma Dealmaker of the Year.” Marc, a partner in the life sciences practice, represents clients in the biotechnology, medical device and pharmaceutical industries in a wide variety of transactions, including license and collaboration agreements, public and private securities offerings and mergers and acquisitions. His 2018 accomplishments include having advised Bain Capital on the creation of Cerevel Therapeutics, and also having represented Vertex Pharmaceuticals in a strategic co-development and co-commercialization agreement with CRISPR Therapeutics, among other key matters for life sciences clients.

The Deal Middle Market awards recognize the leading lawyers, bankers, investors and advisors in transactions up to $500 million in value.

Learn more about our global life sciences practice here.

Cookie Settings